Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
Public ClinicalTrials.gov record NCT05062759. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Adolescent and Young Adult Participants With Moderate to Severe Asthma (VECTOR)
Study identification
- NCT ID
- NCT05062759
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Tezepelumab Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 22, 2021
- Primary completion
- Mar 20, 2022
- Completion
- Jul 17, 2022
- Last update posted
- Jun 21, 2023
2021 – 2022
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Bakersfield | California | 93301 | — |
| Research Site | Huntington Beach | California | 92647 | — |
| Research Site | Miami | Florida | 33133 | — |
| Research Site | Columbia | Missouri | 65203 | — |
| Research Site | Northfield | New Jersey | 08225 | — |
| Research Site | Dayton | Ohio | 45406 | — |
| Research Site | Toledo | Ohio | 43617 | — |
| Research Site | Edmond | Oklahoma | 73034 | — |
| Research Site | Oklahoma City | Oklahoma | 73120 | — |
| Research Site | Dallas | Texas | 75225 | — |
| Research Site | San Antonio | Texas | 78229 | — |
| Research Site | Tyler | Texas | 75708 | — |
| Research Site | Waco | Texas | 76712 | — |
| Research Site | Salt Lake City | Utah | 84107 | — |
| Research Site | Milwaukee | Wisconsin | 53228 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05062759, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 21, 2023 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05062759 live on ClinicalTrials.gov.